AUM Biosciences to merge with SPAC Mountain Crest to go public in US

Singapore-based clinical-stage biotechnology company AUM Biosciences has announced that it has signed a merger agreement with Delaware-based publicly traded special purpose acquisition company (SPAC) Mountain Crest Acquisition Corp. to go public in the US. The transaction reflects a pre-money equity value of US$400 million for AUM Biosciences and is expected to close in Q1 2023. […] The post AUM Biosciences to merge with SPAC Mountain Crest to go public in US appeared first on e27.